Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Capital Leases (2019 - 2021)

Fulcrum Therapeutics (FULC) has disclosed Capital Leases for 3 consecutive years, with $2.6 million as the latest value for Q4 2021.

  • Quarterly Capital Leases fell 15.37% to $2.6 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2021, down 15.37% year-over-year, with the annual reading at $2.6 million for FY2021, 15.37% down from the prior year.
  • Capital Leases for Q4 2021 was $2.6 million at Fulcrum Therapeutics, down from $2.7 million in the prior quarter.
  • The five-year high for Capital Leases was $3.8 million in Q2 2019, with the low at $2.6 million in Q4 2021.
  • Average Capital Leases over 3 years is $3.2 million, with a median of $3.2 million recorded in 2020.
  • The sharpest move saw Capital Leases dropped 12.51% in 2020, then fell 15.37% in 2021.
  • Over 3 years, Capital Leases stood at $3.5 million in 2019, then fell by 13.35% to $3.1 million in 2020, then dropped by 15.37% to $2.6 million in 2021.
  • According to Business Quant data, Capital Leases over the past three periods came in at $2.6 million, $2.7 million, and $2.8 million for Q4 2021, Q3 2021, and Q2 2021 respectively.